The Data Monitoring Committee (DMC) appointed in connection with Tel Aviv-based Kitov Pharmaceuticals’ (TASE: KTOV) Phase III clinical trial of KIT-302 is the subject of the ongoing Israeli Securities Authority (ISA) investigation, the company has said.
Kitov announced that it was being investigated by the ISA in February, stating then that the investigation centered around the company’s public disclosures on KIT-302, which is its lead drug candidate and is intended to treat osteoarthritis pain and hypertension simultaneously.
"The company believes that the ISA’s concerns with respect to the DMC are misguided"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze